A Phase 1/2 interventional study of KH001 and Placebo in Dentin Sensitivity, sponsored by HysensBio Co., Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-26.
Sponsored by HysensBio Co., Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 1/2a study in dentin hypersensitivity patients to assess the safety, tolerability, efficacy and pharmacokinetics of single and multiple doses of KH001.
290 studies on the registry are indexed under Dentin Sensitivity; 48 are open to participants now.
This study's enrollment of 40 is below the median of 60 across 281 interventional studies indexed under Dentin Sensitivity.
Browse Dentin Sensitivity studies →HysensBio Co., Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
[Inclusion criteria]
[Exclusion criteria]
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study consists of sequential dosing cohorts, 8 subjects per cohort will be administered KH001 or placebo.
Drug: KH001
The study consists of sequential dosing cohorts, 8 subjects per cohort will be administered KH001 or placebo.
Drug: Placebo
The study drug is applied to teeth
The placebo is applied to teeth
Number of subjects with adverse events(AEs)
The safety and tolerability of KH001 single and multiple ascending dose are evaluated. Adverse event(AE) is based on abnormal clinical laboratory tests, physical exam results and other medically assessments
Time frame: up to 22 days and 36 days
Change from baseline in VAS(Visual Analogue Score).
VAS scale (0-100mm)
Time frame: up to 22 days and 36 days
Maximum plasma concentration (Cmax) of KH001 single and multiple ascending dose.
Pharmacokinetics parameter derived from plasma
Time frame: 0~24 hours
Area under the concentration-time curve (AUC) of KH001 single and multiple ascending dose
Pharmacokinetics parameter derived from plasma
Time frame: 0~24 hours
Time to reach maximum concentration (Tmax) of KH001 single and multiple ascending dose
Pharmacokinetics parameter derived from plasma
Time frame: 0~24 hours
Elimination half life (t½) of KH001 single and multiple ascending dose
Pharmacokinetics parameter derived from plasma
Time frame: 0~24 hours
Estimate of apparent clearance (CL/F) of KH001 single and multiple ascending dose
Pharmacokinetics parameter derived from plasma
Time frame: 0~24 hours
Change from Baseline in Evaporative Air Sensitivity and Tactile Threshold
pain intensity assessed by 0-3 scale
Time frame: up to 22 days and 36 days
Change from baseline in Dentine Hypersensitivity Experience Questionnaire
assessed by questionnaire
Time frame: up to 22 days and 36 days
Plan to share: No — HysensBio Inc. will not be sharing individual de-identified participant data or other relevant study documents.
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Mar 2023, 20 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: KH001